79 related articles for article (PubMed ID: 25807773)
21. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
22. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
23. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.
Yamamoto N; Nakayama T; Kajita M; Miyake T; Iwamoto T; Kim SJ; Sakai A; Ishihara H; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Feb; 132(1):165-73. PubMed ID: 21594664
[TBL] [Abstract][Full Text] [Related]
24. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis.
Rostad K; Hellwinkel OJ; Haukaas SA; Halvorsen OJ; Øyan AM; Haese A; Budäus L; Albrecht H; Akslen LA; Schlomm T; Kalland KH
APMIS; 2009 Aug; 117(8):575-82. PubMed ID: 19664128
[TBL] [Abstract][Full Text] [Related]
25. [Aberrant promoter methylation as biomarker for molecular cytological diagnosis of lung cancer].
Grote HJ
Verh Dtsch Ges Pathol; 2006; 90():216-26. PubMed ID: 17867600
[TBL] [Abstract][Full Text] [Related]
26. Aberrant methylation of RARbeta2 and APC genes in voided urine as molecular markers for early detection of bilharzial and nonbilharzial bladder cancer.
Eissa S; Swellam M; El-Khouly IM; Kassim SK; Shehata H; Mansour A; Esmat M; Nossier AI; Hamdy MA; Awad NM; El-Ahmady O
Cancer Epidemiol Biomarkers Prev; 2011 Aug; 20(8):1657-64. PubMed ID: 21680534
[TBL] [Abstract][Full Text] [Related]
27. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes.
Luedeke M; Linnert CM; Hofer MD; Surowy HM; Rinckleb AE; Hoegel J; Kuefer R; Rubin MA; Vogel W; Maier C
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3030-5. PubMed ID: 19861517
[TBL] [Abstract][Full Text] [Related]
28. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer.
Ellinger J; Haan K; Heukamp LC; Kahl P; Büttner R; Müller SC; von Ruecker A; Bastian PJ
Prostate; 2008 Jan; 68(1):42-9. PubMed ID: 18004747
[TBL] [Abstract][Full Text] [Related]
29. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling.
Kim YJ; Yoon HY; Kim SK; Kim YW; Kim EJ; Kim IY; Kim WJ
Clin Cancer Res; 2011 Jul; 17(13):4523-30. PubMed ID: 21571867
[TBL] [Abstract][Full Text] [Related]
30. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer.
Hoque MO; Feng Q; Toure P; Dem A; Critchlow CW; Hawes SE; Wood T; Jeronimo C; Rosenbaum E; Stern J; Yu M; Trink B; Kiviat NB; Sidransky D
J Clin Oncol; 2006 Sep; 24(26):4262-9. PubMed ID: 16908936
[TBL] [Abstract][Full Text] [Related]
31. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of RASSF1 promoter methylation in prostate cancer.
Daniunaite K; Jarmalaite S; Kalinauskaite N; Petroska D; Laurinavicius A; Lazutka JR; Jankevicius F
J Urol; 2014 Dec; 192(6):1849-55. PubMed ID: 24980613
[TBL] [Abstract][Full Text] [Related]
33. Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients.
Bryzgunova OE; Morozkin ES; Yarmoschuk SV; Vlassov VV; Laktionov PP
Ann N Y Acad Sci; 2008 Aug; 1137():222-5. PubMed ID: 18837951
[TBL] [Abstract][Full Text] [Related]
34. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.
Urakami S; Shiina H; Enokida H; Kawakami T; Kawamoto K; Hirata H; Tanaka Y; Kikuno N; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2109-16. PubMed ID: 16609023
[TBL] [Abstract][Full Text] [Related]
35. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
36. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation.
Cairns P; Esteller M; Herman JG; Schoenberg M; Jeronimo C; Sanchez-Cespedes M; Chow NH; Grasso M; Wu L; Westra WB; Sidransky D
Clin Cancer Res; 2001 Sep; 7(9):2727-30. PubMed ID: 11555585
[TBL] [Abstract][Full Text] [Related]
37. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients.
Battagli C; Uzzo RG; Dulaimi E; Ibanez de Caceres I; Krassenstein R; Al-Saleem T; Greenberg RE; Cairns P
Cancer Res; 2003 Dec; 63(24):8695-9. PubMed ID: 14695183
[TBL] [Abstract][Full Text] [Related]
38. Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.
Shah RB
Adv Anat Pathol; 2013 Mar; 20(2):117-24. PubMed ID: 23399797
[TBL] [Abstract][Full Text] [Related]
39. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC
J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143
[TBL] [Abstract][Full Text] [Related]
40. The potential use of urine cell free DNA as a marker for cancer.
Salvi S; Martignano F; Molinari C; Gurioli G; Calistri D; De Giorgi U; Conteduca V; Casadio V
Expert Rev Mol Diagn; 2016 Dec; 16(12):1283-1290. PubMed ID: 27796148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
